文献速递免疫规划

口服接种改良活犬细小病毒2b型可诱导全身免疫应答

Oral administration of modified live canine parvovirus type 2b induces systemic immune response.
PubMed 文献 · Vaccine · 2019-10-15

本研究报道了在有母源抗体的6周龄幼犬中口服商业犬细小病毒2b型改良活疫苗的结果。14只幼犬经饵料口服疫苗后,13只在第1次接种后血清学和病毒学检测阳性,1只在第2次接种后转阳。结果表明口服接种可诱导全身免疫,即使存在通常干扰接种的母源抗体滴度。

要点

  • 14只6周龄有母源抗体的幼犬口服犬细小病毒2b型改良活疫苗。
  • 13只幼犬在第1次接种后血清学和病毒学检测阳性。
  • 1只幼犬在第2次接种后血清学和病毒学检测阳性。

核心结论

  • 口服接种改良活犬细小病毒2b型疫苗可能诱导全身免疫,即使存在通常干扰接种的母源抗体滴度。

研究设计与样本

  • 研究对14只6周龄有母源抗体的幼犬经饵料口服商业犬细小病毒2b型改良活疫苗。
  • 在不同接种后天数采集血样和直肠拭子,检测犬细小病毒2型抗体滴度和DNA载量。

主要发现

  • 14只幼犬中,13只在第1次接种后血清学和病毒学检测阳性。
  • 1只幼犬在第2次接种后血清学和病毒学检测阳性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Different strategies have been proposed to overcome maternally derived antibody (MDA) interference with canine parvovirus type 2 (CPV-2) immunisation, including intranasal vaccination, which presents some practical limitations. In the present study, the results of the oral administration of a commercial CPV-2b modified live virus (MLV) vaccine in pups with MDA are reported. The CPV-2b vaccine was orally administered to 14 6-week-old pups with a bait. Blood samples and rectal swabs were collected at different days post-vaccination (dpv) to determine CPV-2 antibody titres and DNA loads. Thirteen pups were positive to serological and virological tests after the first vaccination and one pup became positive after the second vaccine administration. The findings of this study suggest that systemic immunity against CPV-2 may be achieved by the use of an MLV CPV-2b vaccine administered orally even in the presence of MDA titres that usually interfere with vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cavalli A, Desario C, Marinaro M, et al. Oral administration of modified live canine parvovirus type 2b induces systemic immune response. Vaccine. 2019. PMID: 31628031. doi:10.1016/j.vaccine.2019.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。